Artrya (ASX:AYA) won a 36-month commercial contract with Lumus Imaging for the use of the Salix Coronary Anatomy platform, according to a Tuesday filing with the Australian bourse.
Salix is designed to detect critical markers, including high-risk plaque, from CT coronary angiogram scans generated by a photon-counting CT scanner, per the filing.
The contract is expected to bring in revenue through a software-as-a-service subscription model, the filing stated.
Artrya's shares were up 3% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。